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Unexplained Deaths Due to Possibly Infectious Causes in
the United States: Defining the Problem and Designing
Surveillance and Laboratory Approaches
Many new infectious diseases have been iden-
tified in the United States during the last several
decades (1). Among these are AIDS, Legionnaires’
disease, toxic-shock syndrome, hepatitis C, and
most recently, hantavirus pulmonary syndrome;
all caused serious illness and death. In each in-
stance, the disease was recognized through inves-
tigation of illness for which no cause had been
identified. Retrospective studies of these and
other newly recognized infectious diseases often
identified cases that occurred before the recogni-
tion of the new agent; therefore, a more sensitive
detection system may make the earlier recogni-
tion of new infectious agents possible.
Delays in recognizing new infectious agents
have often been substantial. For instance, Le-
gionella pneumophila was established as the
cause of Legionnaires’ disease in 1976 after an
epidemic in Philadelphia, but sporadic cases in
1947 and an outbreak in 1957 were retrospectively
identified (2, 3). Similarly, toxic shock syndrome
was recognized in late 1979 and early 1980, but
retrospective reporting and chart reviews docu-
mented cases as early as 1960 (4). HIV was iden-
tified in 1983 (5) yet retrospective investigations
documented AIDS cases in the late 1970s and
possibly as early as 1968 in the United States (6,
7).
The difficulty of identifying unknown etiologic
agents is part of the reason for delays between the
occurrence and recognition of new infectious dis-
eases. Until recently, to identify new infectious
agents we relied primarily on culture techniques.
For fastidious bacteria such as Legionella sp., and
new viruses, such as HIV, which have very specific
growth requirements, successful isolation usually
required numerous attempts with various culture
systems, often extending over years. Advances in
molecular techniques, including polymerase chain
reaction (PCR) amplification and other DNA- (and
RNA-) based techniques (e.g., representational
difference analysis), allow identification and clas-
sification of unknown etiologic agents without
having to culture them (8-10) and provide clues
concerning appropriate conditions for subsequent
isolation of the agent in culture (11,12).
A more systematic public health approach for
the early detection of unknown infectious agents
is needed. This need was acknowledged in Ad-
dressing Emerging Infectious Diseases Threats: A
Prevention Strategy for the United States, a CDC
publication about emerging infections (13). CDC
has established an emerging infections program
(EIP) network to conduct special population-based
surveillance projects, develop surveillance meth-
ods, pilot and evaluate prevention strategies, and
conduct other epidemiologic and laboratory stud-
ies. In late 1994, CDC funded four programs based
at state health departments and academic institu-
tions in California (Alameda, Contra Costa, Kern,
and San Francisco counties), Connecticut, Minne-
sota, and Oregon. Some projects are conducted at
all program sites and others, depending on local
interest and expertise, at only one or two sites.
Surveillance for unexplained deaths due to pos-
sibly infectious causes (UDPIC) for early detection
of new infectious diseases is one of the core activi-
ties being conducted at all sites. This paper esti-
mates the number of UDPIC at the EIP programs
and summarizes the surveillance and laboratory
approaches that will be used to identify their
cause. This is the first attempt to conduct surveil-
lance for early detection of new infectious diseases
in a large U.S. population.
To estimate the number of deaths that might be
identified in surveillance for UDPIC, we used mul-
tiple cause-of-death data for the United States for
1992 from the National Center for Health Statis-
tics (14). The year 1992 was the most recent for
which national data were available at the time of
this study. The analyses of death records were
restricted to the EIP program populations and age
group (1-49 years of age) in which surveillance for
UDPIC was planned. Multiple cause-of-death
data listed on the National Center for Health
Statistics death record allow for analysis of mor-
tality data based on the different causes (15). The
International Classification of Diseases, 9th Revi-
sion (ICD-9) was used to define UDPIC (16). We
selected 77 codes likely to represent UDPIC when
listed on the death record (Table 1) (17).
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Vol. 2, No. 1 — January-March 1996 47 Emerging Infectious DiseasesTable 1. Selected codes from International Classification of Diseases, 9th revision (ICD-9) used to identify unexplained deaths
due to possibly infectious causes (UDPIC)
007.9 unspecified protozoal intesti-
nal disease
008.5 bacterial enteritis, unspecified
008.8 intestinal infectious due to
other organisms: other or-
ganism, not classified else-
where
009.0 infectious colitis, enteritis,
and gastroenteritis
009.1 colitis, enteritis, and gastroen-
teritis of presumed infec-
tious origin
009.2 infectious diarrhea
009.3 diarrhea of presumed infec-
tious origin
027.9 unspecified zoonotic bacterial
disease
038.9 unspecified septicemia
041.9 bacterial infection in condi-
tions classified elsewhere
and of unspecified site: bacte-
rial infection, unspecified
046.9 unspecified slow virus infec-
tion of the central nervous
system
047.9 unspecified viral meningitis
049.9 unspecified non-arthropod-
borne viral diseases of cen-
tral nervous system
057.9 viral exanthem, unspecified
079.9 viral infection in conditions
classified elsewhere and of
unspecified site: unspecified
viral and chlamydial infec-
tion
099.0 venereal disease, unspecified
136.9 other and unspecified infec-
tious and parasitic diseases:
unspecified infectious and
parasitic diseases
283.1 non-autoimmune hemolytic
anemias
284.8 other specified aplastic ane-
mias
286.6 defibrination syndrome
287.3 primary thrombocytopenia
287.5 thrombocytopenia, unspecified
320.9 meningitis due to unspecified
bacterium
322.9 meningitis, unspecified
323.9 unspecified cause of encephali-
tis
357.0 acute infective polyneuritis
420.9 other and unspecified acute
pericarditis
421.0 acute and subacute bacterial
endocarditis
421.9 acute endocarditis, unspecified
422.9 other and unspecified myo-
carditis
424.9 endocarditis, valve unspecified
425.4 other primary cardiomyopa-
thies
425.9 secondary cardiomyopathy,
unspecified
446.6 thrombotic microangiopathy
465.0 acute laryngopharyngitis
465.8 acute upper respiratory infec-
tions of multiple or unspeci-
fied sites: other multiple
sites
465.9 acute upper respiratory infec-
tions of multiple or unspeci-
fied sites: unspecified site
466.0 acute bronchitis
466.1 acute bronchiolitis
480.9 viral pneumonia, unspecified
482.9 bacterial pneumonia, unspeci-
fied
485 bronchopneumonia, organism
unspecified
486 pneumonia, organism unspeci-
fied
511.9 unspecified pleural effusion
518.4 acute edema of lung, unspeci-
fied
518.8 other diseases of lung
519.9 unspecified disease of respira-
tory system
558 other and unspecified nonin-
fectious gastroenteritis and
colitis
780.6 pyrexia of unknown origin
782.1 rash and other nonspecific
skin eruption
782.7 spontaneous ecchymoses
785.5 shock without mention of
trauma
785.6 enlargement of lymph nodes
786.0 dyspnea and respiratory ab-
normalities
792 nonspecific abnormal findings
in other body substances
792.0 cerebrospinal fluid
792.1 stool contents
792.2 semen
792.3 amniotic fluid
792.4 saliva
792.9 other nonspecific abnormal
findings in body substances
795 nonspecific abnormal histo-
logic and immunologic find-
ings
795.3 nonspecific positive culture
findings
795.4 other nonspecific abnormal
histologic findings
795.7 other nonspecific immu-
nologic findings
796.4 other nonspecific abnormal
findings: other abnormal
clinical findings 
798 sudden death, cause unknown
798.1 instantaneous death
798.2 death occurring in less than
24 hours from the onset of
symptoms, not otherwise ex-
plained
798.9 unattended death
799 other ill-defined and un-
known causes of morbidity
and mortality
799.0 asphyxia
799.1 respiratory failure
799.3 debility, unspecified
799.4 cachexia
799.8 other ill-defined conditions
799.9 other unknown and unspeci-
fied cause
Analyses for UDPIC were restricted to pre-
viously healthy persons 1 to 49 years of age by
excluding persons outside this age-group and
those who had any of the following ICD-9 codes as
an underlying cause of death: 140 to 239.9, neo-
plasms; 250.0 to 250.9, diabetes mellitus; 279.0 to
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nism; 295.5, other disease of spleen; 800 to 999.9,
injury and poisoning; E800 to E998, supplemen-
tary classification of external causes of injury and
poisoning. Patients with HIV disease listed any-
where on the death record were also excluded
(codes 042, 042.0, 042.1, 042.2, 042.9, 043, 043.0,
043.1, 043.2, 043.3, 043.9, 044, 044.0, 044.9, and
795.8) (18).
Deaths meeting the study criteria were identi-
fied along with patient age, gender, race (black,
white, and other), and autopsy status for the four
EIPs (aggregate and by EIP program). To deter-
mine rates of UDPIC, we used 1992 census esti-
mates for the four EIP programs (19).
In 1992, 744 UDPIC were identified among
previously healthy persons 1 to 49 years of age in
the four EIP sites. These deaths accounted for 14%
of all deaths (n = 5,304) among persons 1 to 49
years of age in hospitals and emergency rooms.
Most of the 744 UDPIC occurred among male
patients (60%) and whites (72%) (Table 2). Overall
rates among blacks were almost four times as high
as those among whites (29.5 vs. 7.7 per 100,000).
By site, overall rates ranged from 5.6 (in Minne-
sota) to 14.5 (in California) per 100,000 popula-
tion. These geographic differences could be
accounted for only in part by differences in the
proportions of blacks by site. In Minnesota and
Oregon the proportions of blacks were 2.8% and
1.9%, respectively, whereas in California and Con-
necticut the proportions were 14.7% and 12.4%,
respectively.
Figure 1 shows the age-specific rates of UDPIC
for persons 1 to 49 years of age. Persons 1 to 24
years of age accounted for only 19% of deaths,
while persons 40 to 49 years of age accounted for
50%.
Of selected ICD-9 codes (Table 1), the six dis-
ease classifications (and codes) accounting for the
most of the UDPIC are shown in Table 3.  A se-
lected ICD-9 code was listed as the underlying
cause of death in 253 (34%) of 744 UDPIC. Autop-
sies were performed in 293 (39%) of the 744
UDPIC.
Two approaches for surveillance were proposed
as a basis for the EIP project. In the first, clinicians
will be asked to report unexplained deaths and
serious illnesses from possibly infectious causes.
In the second, death certificate databases will be
used to select patients with ICD-9 codes likely to
represent UDPIC. The first approach allows pro-
spective collection of data and specimens for
deaths and serious illnesses. In the second ap-
proach, UDPIC will be identified retrospectively
through information on death certificates.
Clinicians in the EIP areas have been asked to
report by telephone to EIP program surveillance
personnel all previously healthy persons 1 to 49
years of age who are hospitalized (or admitted to
Figure 1. Age-specific rates of unexplained deaths due
to possibly infectious causes (UDPIC) among
previously healthy persons 1 to 49 years of age in the
four emerging infections program sites, 1992.
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Table 2. Unexplained deaths due to possibly infectious causes (UDPIC) among previously healthy persons by emerging infection
program (EIP) site, 1992  
Rate (per 100,000 population aged 1-49 years)  
Gender               R a c e
EIP site No. of UDPIC Overall Female Male Black White Other  
California
* 316 14.5 10.8 18.5 34.0 12.2 8.9
Connecticut
† 83 14.2 10.5 18.5 37.9 11.4 -
Minnesota 189 5.6 4.8 6.6 11.0 5.4 9.5
Oregon 156 7.2 6.9 7.7 21.8 7.0 7.8
Total 744 8.9 7.4 10.9 29.5 7.7 8.7  
*Alameda, Contra Costa, and San Francisco counties.
†New Haven County.
Age Group (years)
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with hallmarks of an infectious disease for which
no cause is identified. Inclusion and exclusion
criteria are shown below.
Inclusion criteria
1. 1 to 49 years of age
2. Admitted to a hospital or emergency room
with life-threatening illness of potentially in-
fectious etiology
3. No cause for illness identified by preliminary
testing
Exclusion criteria
1. Preexisting chronic medical condition: malig-
nancy; HIV infection; chronic cardiac, pulmo-
nary, renal, hepatic or rheumatologic
disease; or other known underlying chronic
illness (e.g., diabetes mellitus)
2. Immunosuppressive therapy
3. Trauma
4. Toxic ingestion or exposure
5. Nosocomial infection
Clinicians and pathologists in the four EIP pro-
grams were informed of the surveillance system
through a combination of mailings, oral presenta-
tions, and posters.
Classifying patients as having one or more in-
fectious disease-related syndrome(s) as listed be-
low should help identify groups of patients with
similar illnesses for laboratory testing.
  1. Acute abdominal symptoms (e.g, diarrhea, 
pain, nausea/vomiting) and history of (h/o)
fever
  2. Arthritis or osteomyelitis and h/o fever
  3. Blood cell dyscrasia or coagulopathy and h/o 
fever
 4. Conjunctivitis,  keratitis,  endophthalmitis,  or
periocular infection and h/o fever
 5. Endocarditis,  myocarditis,  pericarditis  and
h/o fever
  6. Hepatitis or hepatic insufficiency/failure and
h/o fever
  7. Meningitis, encephalitis, encephalopathy, 
dementia, or other neurologic syndrome
with or without a h/o of fever
  8. Rash, skin or mucosal membrane lesions, cell-
ulitis, myositis, lymphadenitis, or lymph-
angitis and h/o of fever
  9. Renal insufficiency/failure and h/o of fever
10. Respiratory failure, pulmonary infiltrates, or 
other pleuropulmonary manifestation and
h/o of fever
11. Shock or sepsis and h/o of fever or hypother-
mia
12. Other
Information about exposures (e.g., travel or
contact with animals or insects) resulting in infec-
tious diseases will be collected. For patients who
are still alive or have died recently, clinical and
pathology laboratories will be asked to save clini-
cal specimens (including biopsied tissues) ob-
tained during clinical care and diagnostic
evaluation. Range of specimens will vary but be
appropriate for the given illness and organ sys-
tems affected. These specimens will be collected,
divided into aliquots, and stored. Autopsies will be
encouraged. With the exception of pathology speci-
mens, specimens will be initially banked at the
EIP sites. Fixed or frozen tissue specimens (pre-
mortem and postmortem) will be sent directly to
CDC for examination. A CDC pathologist will be
available to consult with the local pathologist and
to discuss preparation and transport of tissues.
Pathology results are expected to guide further
laboratory testing on specimens.
Table 3. Of selected ICD-9 codes, disease classifications accounting for most unexplained deaths due to possibly infectious
causes (UDPIC) in the four study sites, 1992                 
        UDPIC with ICD-9 code included on death record by age group (%)
1–49 yr; 1–14 yr; 15–39 yr; 40–49 yr;
Disease classification (ICD-9)* n = 744 n = 75 n = 295 n = 374
Respiratory failure (799.1) 205 (28) 14 (19) 91 (31) 100 (27)
Unspecified septicemia (038.9) 108 (14) 8 (11) 42 (14) 58 (16)
Pneumonia, organism unspecified (486) 101 (14) 7   (9) 33 (11) 61 (16)
Other primary cardiomyopathy (425.4) 84 (11) 5   (7) 26   (9) 53 (14)
Shock without mention of trauma (785.5) 83 (11) 10 (13) 29 (10) 44 (12)
Other unknown or unspecified (799.9) 75 (10) 9 (12) 35 (12) 31   (8)
Totals
† 505 (68) 39 (52) 193 (65) 273 (73)
*More than one of these disease classifications (ICD-9 code) may be listed on a death record.
†UDPIC with at least one of the six disease classifications included on the death record.
Dispatches
Emerging Infectious Diseases 50 Vol. 2, No. 1 — January-March 1996Clinical and epidemiologic data will be peri-
odically reviewed locally at each EIP and at CDC
in aggregate. Each EIP will identify UDPIC not
reported through the clinician-based system by
using state-based (rather than national) electronic
data systems to reduce delays in relaying informa-
tion. When deaths not reported through the clini-
cian-based system are identified, the medical
chart will be reviewed, the patient’s illness will be
classified by syndrome and information available
in the medical record concerning exposures will be
collected. Samples of specimens will be obtained
at autopsy. Deaths will be handled as in the clini-
cian-based system with regard to periodic review
and laboratory testing, although it is expected
that fewer clinical specimens will be available
from patients whose deaths were not reported
through the clinician-based system.
Additional reference level laboratory tests for
known pathogens will be done in state health
laboratories and CDC. CDC will test for previously
unrecognized infectious agents.
Initial identification of unrecognized etiologic
agents at CDC will primarily rely on serology,
immunohistochemistry, and nucleic acid probes.
When a sufficient number of patients with similar
illnesses are identified, a customized strategy for
laboratory testing will be designed. Serology and
immunohistochemistry will be used to narrow the
scope of possible etiologies. Nucleic acid probes
will be used with PCR to amplify from clinical
specimens specific fragments of genetic material
that can be sequenced and used for phylogenetic
comparisons to known infectious agents.
Clinicians who reported cases will be informed of
laboratory results, but information will usually
not be available in time to affect treatment of
individual patients.
Until now, unexplained deaths and serious ill-
nesses due to possibly infectious causes have not
been addressed as a specific public health prob-
lem. The data obtained in the first phase of this
project suggest that UDPIC in previously healthy
persons account for 13% of hospitalized deaths
among persons 1 to 49 years old in the EIP sites.
Experience in recent years with new infectious
diseases suggests that systematic study of UDPIC
and similarly unexplained serious illnesses may
allow earlier detection of emerging infections. This
has been made more feasible by newly developed
nucleic acid-based methods for identification of
unknown etiologic agents.
Use of the 1992 National Center for Health
Statistics multiple cause-of-death data to esti-
mate the number of UDPIC has its limitations.
The most important is in the selection of ICD-9
codes to identify these deaths. Even with codes
such as 038.9 (“unspecified septicemia”), which
seem relevant, without reviewing the medical re-
cord it is impossible to know if the cause of the
septicemia was known by the clinician but not
specified or was nosocomial. Codes representing
potentially infectious deaths (e.g., 799 for “other
ill-defined and unknown causes of morbidity and
mortality”) might also be assigned to noninfec-
tious deaths. Another critical limitation is failure
to identify deaths that are, in fact, unexplained
but have been given an incorrect diagnosis.
For several reasons, our surveillance is limited
to persons 1 to 49 years of age who have been
healthy. The 1-year lower age limit was selected to
avoid confusion with congenital problems in
infants but include most children in day-care,
where infectious diseases are common and a new
infectious disease might spread rapidly. The upper
age limit was set to exclude an expected increased
proportion of unexplained deaths from noninfec-
tious causes in persons 50 years and older. Many
of the recently recognized life-threatening infec-
tious diseases would have been detected among
previously healthy persons in this age-group. Pre-
viously healthy persons might also be considered
better sentinels for new infectious diseases be-
cause of their generally more vigorous interaction
with people and higher likelihood of exposure to
infections (e.g., travel or contact with animals or
insects). However, restricting surveillance to pre-
viously healthy persons is likely to decrease the
sensitivity of our system. 
Patients who are immunocompromised—
whether from HIV infection, malignancy, or im-
munosuppressive therapy—and many patients
with other chronic illnesses, are more susceptible
to known and unknown infectious diseases. New
infectious diseases first identified in persons who
are immunocompromised or have chronic illnesses
have subsequently been found to also cause infec-
tion in persons with normal immune systems
(20,21). Although sensitivity could be improved by
including these populations in surveillance,
available resources and a concern that laboratory
evaluation would be complicated by the broader
range of infectious possibilities compelled us to
focus on previously healthy persons.
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systems for surveillance and laboratory evalu-
ation are being used in combination because of
their complementary strengths and weaknesses.
The notable strengths of the clinician-based sys-
tem are the contribution of clinicians and the
timeliness of reporting. Because of their training
and their relationship with patients, clinicians can
recognize unusual and potentially new infections.
This system also offers opportunities to collect and
store clinical specimens (pre-mortem and post-
mortem) that would not normally be saved, in
addition to providing systematic and timely collec-
tion of exposure information that might not be
available in the medical record. This system might
also increase the likelihood of an autopsy. How-
ever, reporting is time-consuming and is not likely
to affect the patient’s care, which may lower the
sensitivity of this approach.
The primary strengths of the death certificate–
based system are its completeness and relative
ease, once the data are electronically available.
The completeness may make it sensitive for detec-
tion of new infections resulting in death (but as-
sumes that the correct ICD-9 codes are selected
and that they are coded accurately). Sensitivity is
important because, to be effective, the combined
approaches should detect relatively rare illnesses
(e.g., in the range of one case per 100,000 to
1,000,000 population per year). The main disad-
vantages of this system are the vagaries of ICD-9
classification: codes are not designed to identify
new infectious diseases and are assigned by per-
sons not directly familiar with the case. The list of
ICD-9 codes used to identify UDPIC is likely to be
modified on the basis of information collected in
this system and in the clinician-based system.
Another problem is the delay in getting informa-
tion on the death certificate into the database for
review, which makes this system relatively slow.
Further, the only clinical specimens likely to be
available for laboratory evaluation are those col-
lected at autopsy.
The goal of our project is early detection of new
life-threatening infectious diseases. However, it is
likely that in the process, we will identify cases in
which known, but poorly recognized, infectious
diseases are responsible, either because the
diagnostic tests being used clinically are of poor
sensitivity or because the diagnosis was
unexpected by clinicians. Findings concerning
such cases may be useful in identifying areas in
which better diagnostic capabilities are needed
and in improving estimates of infectious disease
prevalence (22). A population-based bank of clini-
cal specimens will be invaluable in current and
future testing for newly recognized etiologic
agents and for developing diagnostic tests. This
project will better clarify surveillance strategies
and help standardize nucleic acid-based tech-
niques for identification of previously unknown
etiologic agents. Through it, we expect to build
U.S. capacity for detecting and responding to
newly recognized infectious diseases not only at
the EIP sites but elsewhere, nationally and inter-
nationally.
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